MARKET WIRESeeking Alpha • 16h ago
Perrigo: Cheap Valuation Overshadowed By Heavy Debt (NYSE:PRGO)Seeking Alpha report covering Perrigo Company plc (PRGO) market action, institutional positioning, and fundamental catalysts.
Why PRGO Stock slipped -0.75% Today — RQD Quant Desk Flash
$15.78 -0.75% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $15.73
Perrigo Company plc (PRGO) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $2.19B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PRGO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PRGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Perrigo Company plc (NYSE: PRGO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $15.78 (-0.75% 1D, market cap $2.19B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PRGO ranks #274 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PRGO compare to AUPH and XNCR in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRGO carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of 35.1%, and ROIC of -13.6%. By comparison, AUPH (Aurinia Pharmaceuticals Inc) holds a B grade (74/100 RQD, P/E 8.0x, ROIC 16.5%, cap $2.22B) and XNCR (Xencor Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -21.3%, cap $2.22B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while AUPH leads on capital efficiency (16.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PRGO?
▼
Per PRGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001585364), Perrigo Company plc generated $4.25B in revenue (-2.8% YoY), -$1.43B in net income, and $145.1M in free cash flow against $8.54B in total assets and $3.60B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $15.73 (-0.33%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 3.4% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-4.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRGO)Realized 20D OHLCV Swing Band: ±8.1%
Deterministic 5-Pillar Attribution (49/100 Composite)
🔍 WHY PRGO SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (31% of score)
20D Institutional Volume Accumulation (±8.1% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (24% of score)
FRED Regime × Technicals: 57% of 52W Range • RSI-14 at 54.8 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk5/20 pts (-15 pt drag)
Balance-sheet & 10-K footnote risk deducts 15 pts from forensic ceiling
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$15.37+5.2% Next Q
41
Q2 (-2Q)Grade D$16.17-0.9% Next Q
44
Q3 (-1Q)Grade D$16.02-1.5% Next Q
46
CurrentGrade D$15.78-5.4% Hist 90D α
49
Trajectory: D (41) → D (49)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a PRGO Turnaround Squeeze
While PRGO currently carries a cautious 49/100 (D) rating due to SEC 10-K Forensic Risk (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Big institutional funds and options desks are actively positioning on the bullish side.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.89) and Max Pain ($16.57) forces dealer call-delta covering toward $21.68.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRGO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PRGO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PRGO Stock slipped -0.75% Today — RQD Quant Desk Flash
Perrigo Company plc (PRGO) slipped -0.75% to $15.78, trading at 57% of its 52-week range ($9.23 – $20.65). Stretched risk/reward at current multiples (-14% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 57% of its 52-week range ($9.23 – $20.65) with RSI-14 at 54.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±8.1% around $15.78 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 35.1% gross margin and $145.1M annual free cash flow.
Live PRGO Headlines & Catalysts
MARKET WIREYahoo Finance • 19h ago
Perrigo Company plc (PRGO) Stock ForecastsYahoo Finance report covering Perrigo Company plc (PRGO) market action, institutional positioning, and fundamental catalysts.
CATALYSTInvesting.com • 22h ago
Perrigo stock soars 62% after InvestingPro Fair Value call By Investing.comInvesting.com report covering Perrigo Company plc (PRGO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Globe and Mail • 1d ago
Analysts’ Top Healthcare Picks: Perrigo Company (PRGO), IQVIA Holdings (IQV)The Globe and Mail report covering Perrigo Company plc (PRGO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Perrigo (NYSE:PRGO) Stock Price Up 4.5% - Time to Buy?MarketBeat report covering Perrigo Company plc (PRGO) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 1d ago
Perrigo: A Sale, But Not Necessarily A Good One (NYSE:PRGO)Seeking Alpha report covering Perrigo Company plc (PRGO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Perrigo Company plc (NYSE:PRGO) Stock Rated "Hold" by Sell-Side AnalystsMarketBeat report covering Perrigo Company plc (PRGO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Traders Daily • 1d ago
Price-Driven Insight from (PRGO) for Rule-Based StrategyStock Traders Daily report covering Perrigo Company plc (PRGO) market action, institutional positioning, and fundamental catalysts.
CATALYSTBenzinga • 3d ago
Canaccord Genuity Maintains Buy on Perrigo, Raises Price Target to $19Canaccord Genuity analyst Susan Anderson maintains Perrigo (NYSE:PRGO) with a Buy and raises the price target from $17 to $19.
MARKET WIREYahoo • 3d ago
Perrigo exits infant-formula with sale to MeridianMadeNew York-listed Perrigo said the divesture follows a strategic review, concluding a sale is the “best path forward for the business and its stakeholders”.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRGO)
- ✓Walkthrough of PRGO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PRGO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +38.54%📐 HORIZONTAL RANGE
2026-11-03O $15.90H $15.90L $15.78C $15.78VOL 3.35M
RES: $17.45SUP: $8.70SMA50: $14.89SMA200: $12.45
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PRGO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -2.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PRGO today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PRGO. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PRGO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRGO)
Health Care Rank #274 of 1016
⚔️ AUPH vs PRGO Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PRGO vs. AUPH, XNCR, IMNM, VERA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Perrigo Company plc (PRGO) ranks #274 by composite RQD confidence (49/100, grade D) and #242 by equity capitalization ($2.19B). Within this direct 5-issuer industry benchmark cohort, AUPH leads on earnings valuation at 8.0x trailing P/E, while AUPH leads on capital efficiency and profitability with 16.5% ROIC and 88.5% gross margin. AUPH currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with PRGO at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PRGO
ACTIVE
Perrigo Company plc | D | 49/100 | — | 35.1% | -13.6% | -0.75% | $2.19B | Benchmark Subject |
| AUPH Aurinia Pharmaceuticals Inc | B | 74/100 | 8.0x | 88.5% | 16.5% | -3.25% | $2.22B | /auph-vs-prgo → |
| XNCR Xencor Inc. | D | 47/100 | — | — | -21.3% | +2.09% | $2.22B | /xncr-vs-prgo → |
| IMNM Immunome Inc. | E | 26/100 | — | — | -35.0% | -0.44% | $2.15B | /imnm-vs-prgo → |
| VERA Vera Therapeutics Inc. (Class A) | E | 31/100 | — | — | -35.0% | +1.47% | $2.23B | /vera-vs-prgo → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001585364In its most recent audited fiscal period (FY2025, filed 2025-12-31), Perrigo Company plc (PRGO) reported GAAP revenue of $4.25B (-2.8% vs. FY2024 revenue of $4.37B , and -8.6% cumulative change since FY2023) , GAAP net income of -$1.43B, operating cash flow of $238.5M, and free cash flow of $145.1M (-40.7% YoY). On the balance sheet, PRGO closed FY2025 with $8.54B in total assets against $3.60B in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $4.25B | -$1.43B | $238.5M | $145.1M | $8.54B | $3.60B |
| FY2024 (FY) | 2024-12-31 | $4.37B | -$171.8M | $362.9M | $244.6M | $9.65B | $3.58B |
| FY2023 (FY) | 2023-12-31 | $4.66B | -$12.7M | $405.5M | $405.5M | — | — |
3. PRGO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PRGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Perrigo Company plc (NYSE: PRGO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $15.78 (-0.75% 1D, market cap $2.19B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PRGO ranks #274 in composite RQD confidence.
How does PRGO compare to AUPH and XNCR in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRGO carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of 35.1%, and ROIC of -13.6%. By comparison, AUPH (Aurinia Pharmaceuticals Inc) holds a B grade (74/100 RQD, P/E 8.0x, ROIC 16.5%, cap $2.22B) and XNCR (Xencor Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -21.3%, cap $2.22B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while AUPH leads on capital efficiency (16.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PRGO?
Per PRGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001585364), Perrigo Company plc generated $4.25B in revenue (-2.8% YoY), -$1.43B in net income, and $145.1M in free cash flow against $8.54B in total assets and $3.60B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PRGO trading relative to its 50-day, 200-day, and 52-week technical levels?
PRGO last traded at $15.78 (-0.75% on volume of 3,349,385 shares), positioning the stock +5.98% above its 50-day simple moving average ($14.89) and +26.75% above its 200-day simple moving average ($12.45). Across its 52-week range of $9.23 to $20.65, PRGO sits at the 57.4% percentile with a 14-day RSI of 54.8 (NEUTRAL RANGE) and an implied next-earnings move of ±8.1% ($14.50 to $17.06).
PRGO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PRGO stock moving today?
Why PRGO Stock slipped -0.75% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-14% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 49/100 (D)
✓ STAGE-C NUMBER FIREWALL VERIFIED
PRGO — Perrigo Company plc: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:26:22Z
Roarable Rating Brief: What This Means to a Prospective Investor
The per the Roarable RQD rating, PRGO scores 49 out of 100, grade D, labeled "Roarable Sell — Underperform / Distribution Warning." Pillar breakdown:
- Fundamental Cash Engine: 8 / 20. Driven by ROIC of -13.6% and an FCF yield of 6.58%. The cash-yield figure is a supportive element, but negative ROIC indicates capital is not being earned at a return above zero.
- Whale 13F Flow: 15 / 20. Scored on institutional accumulation and options positioning. This is the strongest pillar, indicating some institutional interest, though the source data does not itemize the holders behind it.
- Insider Conviction: 9 / 20. Scored on SEC Form 4 and Congressional PTR cluster flow. The pillar is below midpoint, indicating insider activity does not provide meaningful conviction support.
- Macro Regime Fit: 12 / 20. Beta of 1.0 and sector sensitivity. Market-level volatility is neutral relative to the broad market.
- Forensic Balance Sheet: 5 / 20. Altman Z of 0.2, Piotroski F of 5/9, Debt/Equity of 1.23. This is the weakest pillar and the primary driver of the low overall score; the Altman Z-Score sits in a distress-range value per the source data's scoring.
For a prospective investor, the upside case rests on the FCF yield and the institutional flow pillar; the downside case rests on negative operating and net margins, negative ROIC, a weak balance sheet pillar, and the distribution-warning verdict. Valuation appears inexpensive on the surface (dividend yield of 7.22%), but the source data does not provide earnings-based multiples, so valuation tradeoffs cannot be measured against earnings. Leverage is the central tradeoff: the cash yield and dividend yield are being offset by a balance sheet pillar scoring 5 / 20.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 (filed 2025-12-31) | $4253.1M | $-1122.2M | $-1425.4M | N/A | $145.1M | N/A | $3603.6M |
| FY 2024 (filed 2024-12-31) | $4373.4M | $112.9M | $-171.8M | N/A | $244.6M | $558.8M | $3581.7M |
| FY 2023 (filed 2023-12-31) | $4655.6M | $151.9M | $-12.7M | N/A | $405.5M | N/A | N/A |
Per the market data, gross margin is 35.1%, operating margin is -26.4%, and net margin is -33.5%. ROIC is -13.6%. Per the Roarable RQD rating, the Altman Z-Score is 0.2, the Piotroski F-Score is 5/9, and Debt/Equity is 1.23. Reported revenue declined across the three periods, and operating income moved from positive in FY 2023 and FY 2024 to negative in FY 2025. The balance sheet shows reported debt of $3603.6M against cash that is available only for FY 2024 ($558.8M).
Recent Catalysts & News Wire Analysis
Per the recent news wire, six items reference PRGO. Headlines include a Seeking Alpha piece titled "Perrigo: Cheap Valuation Overshadowed By Heavy Debt," a Yahoo Finance stock forecast item, an Investing.com item tagged as a CATALYST describing a 62% stock move following an InvestingPro Fair Value call, a Globe and Mail analyst picks item, a MarketBeat item reporting a 4.5% price rise, and a second Seeking Alpha item titled "Perrigo: A Sale, But Not Necessarily A Good One." The only item flagged GREEN is the Investing.com catalyst; the remaining items are YELLOW market-wire items. The butterfly supply-chain graph reports no supply chain links and no proprietary signals. Risk watch items per the news wire center on the debt burden referenced in the headlines.
Open Questions
- What is the composition of the debt in the $3603.6M figure, including maturity schedule and interest cost? The source data does not break this down.
- What drove the FY 2025 swing to a $-1425.4M net loss and $-1122.2M operating loss, and is it recurring or one-time?
- What is the FY 2025 cash balance? The source lists cash as N/A for FY 2025 and FY 2023.
- What are the EPS figures for any period? All reported EPS values are N/A.
- Who are the institutional and insider holders behind the whale-flow and insider pillar scores? The holders section is empty.
PRGO Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Perrigo Company plc (PRGO) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Seeking Alpha • 16h ago
Perrigo: Cheap Valuation Overshadowed By Heavy Debt (NYSE:PRGO) Seeking Alpha report covering Perrigo Company plc (PRGO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 19h ago
Perrigo Company plc (PRGO) Stock Forecasts Yahoo Finance report covering Perrigo Company plc (PRGO) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Investing.com • 22h ago
Perrigo stock soars 62% after InvestingPro Fair Value call By Investing.com Investing.com report covering Perrigo Company plc (PRGO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 1d ago
Analysts’ Top Healthcare Picks: Perrigo Company (PRGO), IQVIA Holdings (IQV) The Globe and Mail report covering Perrigo Company plc (PRGO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Perrigo (NYSE:PRGO) Stock Price Up 4.5% - Time to Buy? MarketBeat report covering Perrigo Company plc (PRGO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
Perrigo: A Sale, But Not Necessarily A Good One (NYSE:PRGO) Seeking Alpha report covering Perrigo Company plc (PRGO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Perrigo Company plc (NYSE:PRGO) Stock Rated "Hold" by Sell-Side Analysts MarketBeat report covering Perrigo Company plc (PRGO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Traders Daily • 1d ago
Price-Driven Insight from (PRGO) for Rule-Based Strategy Stock Traders Daily report covering Perrigo Company plc (PRGO) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
PRGO Bull vs. Bear Conversation Board — What's Your Call at $15.78?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRGO 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $17.17 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is PRGO (D • RQD 49/100) a Buy at $15.90?
Welcome to the PRGO (Perrigo Company plc) Roar Pit. Current RQD Composite is 49/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $11.93 (-25.0%)
Spot @ $15.90 Pump the brakes on PRGO — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on PRGO, but look at what you are paying: current EV/EBITDA multiples with 35.1% gross margins. Unless Perrigo Company plc expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH
🎯 Target: $18.76 (+18.0%)
Spot @ $15.90 PRGO cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on PRGO, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $15.90 (52-wk range $9.23 - $21.01), any beat on forward guidance forces shorts and underweight funds to chase.